<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757692</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-011</org_study_id>
    <nct_id>NCT00757692</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.</brief_title>
  <official_title>A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose To define the efficacy, tolerability and safety of Vandetanib in combination with
      bicalutamide in patients with chemotherapy naive hormone refractory prostate cancer

      Hypothesis There will be a PSA response when Vandetanib is given in combination with
      Bicalutamide in Chemotherapy Naive Hormone refractory prostate cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the advent of PSA surveillance, many patients diagnosed with hormone refractory disease,
      have PSA rising disease only, are asymptomatic, with no evidence of metastatic disease. There
      is no standard of care in this patient population. A standard treatment in this population
      has been the addition of a non-steroidal anti androgen such as bicalutamide. PSA response
      rate (defined as a 50% decrease) have been reported in 20% range with bicalutamide.

      Even in patients with hormone refractory prostate cancer (HRPC) and metastases that have no
      cancer related symptoms, initiation of chemotherapy is controversial given the palliative
      nature of chemotherapy and potential for serious toxicity.

      These patients are generally well enough to to undergo trials of novel agents and achieve
      adequate drug exposure, such that any cytostatic effect will be apparent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response</measure>
    <time_frame>Continuous to end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to over all progression</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment related toxicity</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bicalutamide at 50 mg will be administered orally, daily and continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Bicalutamide at 50 mg will be administered orally, daily and continuously.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a pathological diagnosis of adenocarcinoma of the prostate

          -  Patients must have biochemically recurrent disease or metastatic disease that is
             asymptomatic or minimally symptomatic (total daily morphine dose &lt; 30mg.day) for which
             no curative therapy exists.

          -  Patients must have documented evidence od PSA progression while receiving androgen
             ablative therapy (i.e. must be hormone refractory). Progression is defined as the
             development of new metastatic lesions, or rising PSA defined as at least two rises in
             PSA at least 1 week apart. If the second PSA is not rising, a thrid PSA is required to
             show further increase; if not, a subsequent level must show further increase. The
             third (or subsequent) PSA confirming progression must be within 2 weeks of
             randomization.

          -  The PSA must be =&gt; 2ug/L at the time of study entry.

          -  ECOG performance status of 0 or 1

          -  Age =&gt;18 years

          -  Patients must have a life expectancy of at least 12 weeks

          -  No Prior chemotherapy is permissible for hormone refractory disease. Chemotherapy may
             have been received in a neoadjuvant or adjuvant setting provided it was given 12
             months prior to registration.

          -  Hormone Therapy

               -  Prior hormone therapy in the form of either medical or surgical castration is
                  required. If the patient is receiving medical androgen abalation a castrate level
                  of testosterone (1.7nmol/L) must be present. Therapy with LHRH agonist must
                  continue for those prostate cancer patients already receiving this treatment at
                  the time of registration. If the patients has discontinued the LHRH agonist, this
                  must be restarted and a castrate level of testosterone must be present.

               -  Prior use of nonsteroidal antiandrogens (including bicalutamide) is permitted but
                  must have been discontinued 6 weeks prior to registration.

          -  Prior external beam radiation is permitted provided a minimum of 4 weeks has elapsed
             between the last dose and registration in the trial. Exceptions will be made for
             limited field, single fraction palliative radiation to bone.

          -  No concurrent treatment with steriods unless steriods have been ingested for 4 weeks
             prior to commencing study at a dose of less than or equal to an equivalent of
             prednisone 20mg per day.

          -  No concurrent experimental trial medication is permitted. No prior use of VEGF/VEGFR
             or EGFR targeting agents for hormone refractory disease is permitted.

          -  Laboratory Requirements- within 7 calendar days prior to registration Hematology:
             haemoglobin &gt;= 100g/L neutrophils &gt;=1.5 x 10(9)/L Platelets &gt;=100 x 10(9)/L INR =&lt;1.5
             x upper limit of normal Biochemistry: AST, ALT = &lt;1.5 x upperlimit of normal Bilirubin
             &lt;1.5 x upper limit of normal Serum creatinine &lt;1.5 x upper limit of normal

          -  Baseline QTc (Bazett's) &lt;480msec determined by the average of a least 3 consecutive
             electrocardiograms (ECG) taken within 5-10 mins of each other.

          -  Patient consent must be obtained according to local institutional and/or University
             Research and Ethic Board (REB) requirements.

          -  Patients must be accessible for treatment and follow up.

          -  Protocol treatment is to begin within 7 calendar days of patient registration.

        Exclusion Criteria:

          -  Patients with a history of other invasive malignancy, except:adequately treated non
             melanoma skin cancer or other solid tumors curatively treated with no evidence of
             disease for 3 years.

          -  Patients with known brain metastases or leptomemingeal disease are excluded from this
             clinical trial because of their poor prognosis and because they often develop
             progressive neurological dysfunction that would confound the evaluation of nerologic
             and other adverse events.

          -  History of allergic reactions and/or sensitivity attributed to compounds of similar
             chemical or biological composition to Vandetanib or other agents used in the study.

          -  Other serious intercurrent illness or medical condition that might be aggravated by
             protocol treatment including;myocardial infarction within 6 months prior to study
             entry, congestive heart failure, unstable angina,cardiomyopathy, unstable ventricular
             arrhythmias,OTc (Bazett's) &gt;480msec Uncontrolled hypertension (systolic &gt;160, diatolic
             &gt;100) Uncontrolled psychotic disorders, serious infections,peptic ulcer
             disease,history of bleeding diathesis

          -  Upper gasrtointerstinal or other conditions that would preclude compliance with oral
             medication

          -  Patients with immune deficiency are at increased risk of lethal infections when
             treated with Marrow-suppressive therapy. Therefore, HIV positive patients receiving
             combination ant-retroviral therapy are excluded from study because of possible risk of
             lethal infection and additionally because of the possible pharmacokinetic interactions
             with Vandetanib. Appropriate studies will be undertaken in patients receiving
             combination anti-retroviral therapy when indicated.

          -  Patients who require escalating amounts of narcotic therapy to control pain e.g.
             morphine equivalent dose &gt;30mg/day) since these patients would more appropriately be
             offered systemic chemotherapy

          -  Patients who require therapeutic anticoagulation with warfarin.

          -  Patients who require the following medication:concomittant use of warfarin, Class 1A
             antiarrythmics (e.g., quinidine, procainamide, disopyramide) Class

             1C antiarrhythmics (e.g.,flecainide, propafenone), Class III antiarrhythmics (e.g.,
             amiodarone, sotalol, ibutilide), antipsychotics (e.g., thioridazine, chlorpromazine,
             pimozide, haloperidol, droperidol), tri/tetracyclic antidepressants (e.g.,
             amitriptyline, imipramine, maprotiline), ketoconazole, antiepileptics and macrolide
             antibiotics.

          -  Patients who cannot stop ingestion of grapefruit/juice.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Chi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BC Cancer Agency - Vancouver Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Agency - Centre for Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vandetanib (ZD6474)</keyword>
  <keyword>Hormone</keyword>
  <keyword>Refractory</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Na√Øve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

